Roche joins the COVID-19 antiviral drug race, betting $350M on a startup

Roche joins the COVID-19 antiviral drug race, betting $350M on a startup

Submitted by admin on October 22, 2020 - 10:51am
Source: 
BioPharma Dive
News Tags: 
Roche
antivirals
Atea Pharmaceuticals
COVID-19
AT-527
Headline: 
Roche joins the COVID-19 antiviral drug race, betting $350M on a startup
snippet: 

Roche will pay $350 million in cash for partial rights to an oral antiviral drug that the Boston biotech Atea Pharmaceuticals has been developing to treat COVID-19.

Do Not Allow Advertisers to Use My Personal information